Clinical Trials Browser

Phase EARLY_PHASE1 × OTHER × tremelimumab × Clear all

NCT02812420 2026-03-05

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Phase EARLY_PHASE1 Active not recruiting

Hydronephrosis, Ureteral Neoplasms, Urethral Neoplasms

NCT04005690 2026-02-27

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Phase EARLY_PHASE1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03132467 2024-06-05

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

Phase EARLY_PHASE1 Completed

16 enrolled 8 charts

Anatomic Stage II Breast Cancer AJCC v8

NCT02626130 2022-07-07

Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer

Phase EARLY_PHASE1 Completed

Carcinoma, Renal Cell

NCT04223648 2021-11-22

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Phase EARLY_PHASE1 Withdrawn

Melanoma